|
|
Article: Cost-effectiveness of antiviral stockpiling and near-patient testing for potential influenza pandemic.(RESEARCH)
- Article from:
- Emerging Infectious Diseases
- Article date:
- February 1, 2008
- Author:
CopyrightCOPYRIGHT 2008 U.S. National Center for Infectious Diseases. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
A decision analytical model was developed to investigate the cost-effectiveness of stockpiling antiviral (AV) drugs for a potential influenza pandemic in the United Kingdom and the possible role of near-patient testing in conserving AV drug stocks. Under base-case assumptions (including a fixed stockpile that was smaller than the clinical attack rate), the treat-only option (treating all symptomatic patients with AV drugs) would be considered cost-effective (1,900 [pounds sterling]-13,700 [pounds sterling] per quality-adjusted life year [QALY] gained, depending on the fatality scenario), compared with no intervention (nonintervention but management of cases as they arise). ...